Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians


Von Willebrand Factor (vWF) is a large glycoprotein with a broad range of physiological and pathological functions in health and disease. While vWF is critical for normal hemostasis, vascular integrity and repair, quantitative and qualitative abnormalities in the molecule can predispose to serious bleeding and thrombosis. The heritable form of von Willebrand Disease was first described nearly a century ago, but more recently, recognition of an acquired condition known as acquired von Willebrand Syndrome (AVWF) has emerged in persons with hematological, endocrine and cardiovascular diseases, disorders and conditions. An in-depth understanding of the causes, diagnostic approach and management of AVWS is important for practicing clinicians.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2


  1. 1.

    Lassila R, Lindberg O (2013) Erik von Willebrand. Haemophilia 19(5):643–647

  2. 2.

    Ruggeri ZM (2000) Role of von Willebrand factor in platelet thrombus formation. Ann Med 32(Suppl 1):2–9

  3. 3.

    Huisman B et al (2017) Modeling the cleavage of von Willebrand factor by ADAMTS13 protease in shear flow. Med Eng Phys 48:14–22

  4. 4.

    Sadler JE (1998) Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 67:395–424

  5. 5.

    Valentijn KM et al (2011) Functional architecture of Weibel–Palade bodies. Blood 117(19):5033–5043

  6. 6.

    Favaloro EJ, Pasalic L, Curnow J (2016) Type 2 M and Type 2A von Willebrand disease: similar but Different. Semin Thromb Hemost 42(5):483–497

  7. 7.

    Xu ER, Blythe EE (2017) Structural analyses of von Willebrand factor C domains of collagen 2A and CCN3 reveal an alternative mode of binding to bone morphogenetic protein-2. J Biol Chem 292(30):12516–12527

  8. 8.

    Casa LDC, Ku DN (2017) Thrombus formation at high shear rates. Annu Rev Biomed Eng 19:415–433

  9. 9.

    Lynch CJ, Lane DA, Luken BM (2014) Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWF. Blood 123(16):2585–2592

  10. 10.

    Zhang X et al (2009) Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 324(5932):1330–1334

  11. 11.

    Bharati KP, Prashanth UR (2011) Von Willebrand disease: an overview. Indian J Pharm Sci 73(1):7–16

  12. 12.

    Dayananda KM et al (2010) von Willebrand factor self-association on platelet GpIbalpha under hydrodynamic shear: effect on shear-induced platelet activation. Blood 116(19):3990–3998

  13. 13.

    Rack K, Huck V (2017) Margination and stretching of von Willebrand factor in the blood stream enable adhesion. 7(1):14278

  14. 14.

    Coenen DM, Mastenbroek TG (2017) Cosemans, J, Platelet interaction with activated endothelium: mechanistic insights from microfluidics. Blood. 130(26):2819–2828

  15. 15.

    Meyer D et al (2001) Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Best Pract Res Clin Haematol 14(2):349–364

  16. 16.

    Sutherland JJ et al (2004) Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. J Mol Model 10(4):259–270

  17. 17.

    Dong JF et al (2003) ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 278(32):29633–29639

  18. 18.

    Brown SA et al (2003) Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost 1(8):1714–1717

  19. 19.

    Sztukowska M et al (2008) Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Br J Haematol 143(1):107–114

  20. 20.

    Gallinaro L et al (2008) A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 111(7):3540–3545

  21. 21.

    Gill JC et al (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69(6):1691–1695

  22. 22.

    van Schooten CJ et al (2008) Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 112(5):1704–1712

  23. 23.

    Casari C et al (2013) Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. Blood 122(16):2893–2902

  24. 24.

    Grewal PK et al (2008) The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 14(6):648–655

  25. 25.

    Pegon JN et al (2012) Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica 97(12):1855–1863

  26. 26.

    Christodoulides N et al (2001) Glycoprotein Ib/IX/V binding to the membrane skeleton maintains shear-induced platelet aggregation. Thromb Res 102(2):133–142

  27. 27.

    Jy W et al (2005) Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost 3(6):1301–1308

  28. 28.

    Yuan, Y., et al., Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets. Distinct roles for glycoprotein Ib-V-IX and glycoprotein IIb-IIIa (integrin alphaIIbbeta3) in von Willebrand factor-induced signal transduction. J Biol Chem, 1997. 272(35): p. 21847-54

  29. 29.

    Randi AM, Smith KE, Castaman G (2018) von Willebrand factor regulation of blood vessel formation. Blood 132(2):132–140

  30. 30.

    Zimmerman TS, Ratnoff OD, Powell AE (1971) Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand’s dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 50(1):244–254

  31. 31.

    Boender, J., et al., Clinically relevant differences between assays for von Willebrand factor activity. J Thromb Haemost, 2018

  32. 32.

    Just S (2017) Laboratory Testing for von Willebrand Disease: the Past, Present, and Future State of Play for von Willebrand Factor Assays that Measure Platelet Binding Activity, with or without Ristocetin. Semin Thromb Hemost 43(1):75–91

  33. 33.

    Nichols WL et al (2008) von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 14(2):171–232

  34. 34.

    Chapin J (2018) Von Willebrand disease in the elderly: clinical perspectives. Clin Interv Aging 13:1531–1541

  35. 35.

    Favaloro EJ et al (2018) Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: a large international cross-laboratory study. Thromb Res 166:96–105

  36. 36.

    Tiede A et al (2011) How I treat the acquired von Willebrand syndrome. Blood 117(25):6777–6785

  37. 37.

    Deconinck S et al (2018) Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device-induced acquired von Willebrand syndrome. Res Pract Thromb Haemost 2(4):762–766

  38. 38.

    Waldow HC et al (2014) Acquired von Willebrand syndrome in adult patients with congenital heart disease. Int J Cardiol 176(3):739–745

  39. 39.

    Binnetoglu FK et al (2016) Acquired von Willebrand syndrome in children with aortic and pulmonary stenosis. Cardiovasc J Afr 27(4):222–227

  40. 40.

    Massyn, M.W. and S.A. Khan, Heyde syndrome: a common diagnosis in older patients with severe aortic stenosis. Age Ageing, 2009. 38(3): p. 267-70; discussion 251

  41. 41.

    Warkentin TE, Moore JC (2010) Heyde’s syndrome: from controversy to mainstream. Thromb Haemost 103(2):251–253

  42. 42.

    Vincentelli A et al (2003) Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 349(4):343–349

  43. 43.

    Ibrahim H, Rondina MT, Kleiman NS (2018) Von Willebrand factor and the aortic valve: concepts that are important in the transcatheter aortic valve replacement era. Thromb Res 170:20–27

  44. 44.

    Van Belle E et al (2016) Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement. N Engl J Med 375(4):335–344

  45. 45.

    Froom P et al (1988) Von Willebrand factor and mitral valve prolapse. Thromb Haemost 60(2):230–231

  46. 46.

    Blackshear JL et al (2011) Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy. Mayo Clin Proc 86(3):219–224

  47. 47.

    Onimoe G et al (2011) Acquired von Willebrand Syndrome in congenital heart disease: does it promote an increased bleeding risk? Br J Haematol 155(5):622–624

  48. 48.

    Federici AB et al (2013) Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost 39(2):191–201

  49. 49.

    Bongers TN et al (2006) High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 37(11):2672–2677

  50. 50.

    Pedrazzini G et al (2016) Acquired intracoronary ADAMTS13 deficiency and VWF retention at sites of critical coronary stenosis in patients with STEMI. Blood 127(23):2934–2936

  51. 51.

    Jacquemin M, Peerlinck K (2015) Free hemoglobin: a boost to platelet thrombi. Blood 126(20):2262–2263

  52. 52.

    Muslem R, Caliskan K, Leebeek FWG (2018) Acquired coagulopathy in patients with left ventricular assist devices. J Thromb Haemost 16(3):429–440

  53. 53.

    Da Q et al (2014) Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress. Blood 123(17):2715–2721

  54. 54.

    Selvam SN et al (2017) Abnormal angiogenesis in blood outgrowth endothelial cells derived from von Willebrand disease patients. Blood Coagul Fibrinolysis 28(7):521–533

  55. 55.

    Bartoli CR et al (2018) Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von Willebrand Factor Degradation Alters Angiogenesis. Circ Heart Fail 11(9):e004638

  56. 56.

    Starling RC et al (2014) Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 370(1):33–40

  57. 57.

    Zhou Z et al (2009) Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 101(6):1070–1077

  58. 58.

    Arkebauer MR et al (2011) Carbon monoxide and nitric oxide modulate alpha(2)-antiplasmin and plasmin activity: role of heme. Blood Coagul Fibrinolysis 22(8):712–719

  59. 59.

    Meyer AL et al (2014) Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail 2(2):141–145

  60. 60.

    Shankaran H, Neelamegham S (2004) Hydrodynamic forces applied on intercellular bonds, soluble molecules, and cell-surface receptors. Biophys J 86(1 Pt 1):576–588

  61. 61.

    Shim K et al (2008) Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 111(2):651–657

  62. 62.

    Letsou GV et al (2005) Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant 24(1):105–109

  63. 63.

    Uriel N et al (2014) Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon. J Heart Lung Transplant 33(1):51–59

  64. 64.

    Vincent F et al (2018) Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support. J Am Coll Cardiol 71(19):2106–2118

  65. 65.

    Brehm MA et al (2014) von Willebrand disease type 2A phenotypes IIC, IID and IIE: a day in the life of shear-stressed mutant von Willebrand factor. Thromb Haemost 112(1):96–108

  66. 66.

    Keesler DA, Flood VH (2018) Current issues in diagnosis and treatment of von Willebrand disease. Research and Practice in Thrombosis and Haemostasis 2(1):34–41

  67. 67.

    Draper K et al (2015) Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol. J Heart Lung Transplant 34(1):132–134

  68. 68.

    Borel-Derlon A et al (2007) Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 5(6):1115–1124

  69. 69.

    Grosman-Rimon L et al (2018) The Physiological Rationale for Incorporating Pulsatility in Continuous-Flow Left Ventricular Assist Devices. Cardiol Rev 26(6):294–301

  70. 70.

    Edwards AL et al (2018) Association of Pulsatility with Gastrointestinal Bleeding in a Cohort of HeartMate II Recipients. ASAIO J 64(4):472–479

  71. 71.

    Halder LC et al (2017) Time in Therapeutic Range for Left Ventricular Assist Device Patients Anticoagulated With Warfarin: a Correlation to Clinical Outcomes. ASAIO J 63(1):37–40

  72. 72.

    Molina TL et al (2018) Gastrointestinal Bleeding in Left Ventricular Assist Device: octreotide and Other Treatment Modalities. ASAIO J 64(4):433–439

  73. 73.

    Hollis IB et al (2017) Inhaled Desmopressin for Refractory Gastrointestinal Bleeding in a Patient With a HeartMate II Left Ventricular Assist Device. ASAIO J 63(4):e47–e49

  74. 74.

    Goudemand J et al (2005) Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost 3(10):2219–2227

  75. 75.

    Tsai HM et al (1997) Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834 W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood 89(6):1954–1962

  76. 76.

    Rauch A et al (2014) Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices. Thromb Haemost 112(5):1014–1023

  77. 77.

    Lenting PJ, Christophe OD, Denis CV (2015) von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 25(13):2019–2028

Download references

Author information

Correspondence to Richard C. Becker.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mehta, R., Athar, M., Girgis, S. et al. Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians. J Thromb Thrombolysis 48, 14–26 (2019).

Download citation


  • Von Willebrand Factor
  • Acquired Von Willebrand Syndrome